I am a Healthcare Professional outside the US and UK

I am a Healthcare Professional outside the US and UK

Click here for international medical scientific information about Oncology for Healthcare Professionals.

I am not a Healthcare Professional and I am outside the US and the UK

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information for patients, caregivers and the general public.

Country-specific medical scientific information

Country-specific medical scientific information

Country-specific medical scientific information for Healthcare Professionals.

This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com

2018: Conversations in Oncology in China

Conversations in Oncology

In November 2018, the 15th meeting of the “Conversations in Oncology” series took place in Shanghai, China.

 

This multidisciplinary meeting featured talks from internationally renowned experts discussing key topics in lung cancer, including therapeutic advances, biomarker testing, diagnostic and treatment challenges, and sequencing of therapy. Treatment advances for special patient populations, such as patients with brain metastases or uncommon mutations, were also considered during the meeting.

Conversations in Oncology

To access key presentations from Conversations in Oncology 2018, simply click on the item of your choice below.

Noemi Reguart, MD, PhD

EGFR TKI Sequencing: Does Order Matter?

Presenter(s): Noemi Reguart, MD, PhD
Jin-Seok Ahn, MD, PhD

Treatment Options for NSCLC Patients With Uncommon Mutations

Presenter(s): Jin-Seok Ahn, MD, PhD
Darren Wan-Teck Lim, MBBS, MRCP

Are EGFR TKIs Treatment Options for NSCLC With Brain Metastases?

Presenter(s): Darren Wan-Teck Lim, MBBS, MRCP
Yi-Long Wu, MD, FACS

Treating Lung Cancer in the Real World

Presenter(s): Yi-Long Wu, MD, FACS
Noemi Reguart, MD, PhD

Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung

Presenter(s): Noemi Reguart, MD, PhD

Find out more about other oncology events

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.

 

Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.

 

© 2018 Boehringer Ingelheim International GmbH. All rights reserved.

 

Last updated: November 2018